reports
QuickView: Nearing transition to a commercial story
Aeterna Zentaris is poised to transition to a commercial entity in 2015. Macrilen has an FDA PDUFA date of 5 November in the evaluation of adult growth hormone deficiency (AGHD), a category currently dominated by insulin tolerance tests. Aeterna plans to launch Macrilen in January 2015, if approved. With $39m in cash at 30 June 2014, Aeterna is funded through the reporting of key interim data from its Phase III study of zoptarelin doxorubicin for advanced endometrial cancer, expected near mid-20...
QuickView: ZoptEC moving ahead
Aeterna Zentaris reported at the 2014 ASCO that 158 patients have been randomised as of 26 May 2014 in the zoptarelin doxorubicin in endometrial cancer (ZoptEC) Phase III trial, moving closer to the first interim analysis scheduled to take place in mid-2015. It has cash and cash equivalents of $45.8m at the end of March 2014, which should be enough to support its operation into mid-2015 when the first interim analysis of ZoptEC takes place.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.